研究目的：檢視新式核基質蛋白22(NMP22)免疫分析套件（利用偵尿液中細胞核有絲分裂的蛋白來檢測膀胱癌）是否對我國病人亦為有效。材料與方法：我們用三十位膀胱癌病人、二十位攝護腺肥大病人、二十位泌尿道感染的病人及二十位健康且沒有泌尿道疾病病人的尿液做NMP22免疫分析。每位病人提供尿液滴在NMP22的免疫分析套件上，並於三十分鐘內做判讀。結果：在健康且沒有泌尿道疾病病人及攝護腺肥大病人，NMP22免疫分析法的假陽性率為5％和10％而在泌尿道感染的病人，其假陽性率高達25％。結論：NMP22為一種快速、簡單且不具侵入性用來輔助追蹤膀胱癌病人的工具。但若是膀胱癌的病人合併有泌尿道感染，則需其他工具以協助確立診斷。

OBJECTIVE: This trial attempted to evaluate an immunoassay for urinary nuclear matrix protein (NMP22© BladderCheK™ test), as an indicator for transitional cell carcinoma of the bladder. MATERIALS AND METHODS: Four groups of subjects participated in this trial of urinary NMP 22: group I, consisted of 30 patients with proven transitional cell carcinoma of the bladder; group II, consisted of 20 patients with urinary tract infection; group Ill, consisted of 20 patients with benign prostatic hyperplasia; and group iv, consisted of 20 healthy volunteers. Each subject provided a single urine sample for analysis at the time of study entry. Each sample was stabilized with the NMP test kit and was interpreted within 30 minutes. RESULTS: In healthy volunteers and subjects with benign prostatic hyperplasia the respective false-positive rates of the NMP22® BladderCheK™ test were 5% and 10%. The false-positive rate in patients with urinary tract infection was 25%. In patients with transitional cell carcinoma of bladder, the sensitivity was 67%. CONCLUSIONS: The urinary NMP22® BladderCheK™ test is a sample, non-invasive marker for the detection of bladder cancer. However, for urinary bladder cancer patients complicated with urinary tract infection, we suggest that this test should be used in conjugation with other diagnostic procedures.